EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Postoperative adjuvant chemotherapy and chemoimmunotherapy after radical resection for biliary tract cancer: a retrospective study

Postoperative adjuvante Chemotherapie und Chemoimmuntherapie nach radikaler Resektion bei biliärem Traktkarzinom: retrospektive Studie

Yuhuai Peng, Guoyi Xia, Yufeng Li, Jia Zhou, Sulai Liu, Chuang Peng, Yuewei Tao, Ou Li, Yinghui Song iD

The Oncologist · 04.06.2025 · 30 (6)

DOI: 10.1093/oncolo/oyaf163 ↗

Auf einen Blick

Bei 219 Patient:innen mit biliärem Traktkarzinom war die Chemoimmuntherapie nach Operation mit längerer Gesamtüberlebenszeit verbunden als Operation allein oder adjuvante Chemotherapie. Das rezidivfreie Überleben unterschied sich nicht signifikant.

Fragestellung

Welchen klinischen Wert haben adjuvante Chemotherapie und adjuvante Chemoimmuntherapie nach radikaler Resektion bei biliären Traktkarzinomen?

Methode

Retrospektive Studie mit Daten aus dem Hunan Provincial People’s Hospital von Januar 2020 bis Juli 2024; Kaplan-Meier-Analyse, Cox-Regression, PSM 1:1.

Ergebnisse

219 Patient:innen: 87 Operation allein, 69 adjuvante Chemotherapie, 63 adjuvante Chemoimmuntherapie. RFS: 13,20 vs. 20,40 vs. 19,68 Monate; P=.195. OS: 29,20 vs. 31,5 vs. 43,27 Monate; P=.003. Nach PSM OS 45,27 vs. 29,40 Monate; P=.015.

Schlussfolgerung der Autor:innen

Die Sicherheit der Chemoimmuntherapie war akzeptabel und sie konnte das Gesamtüberleben von BTC signifikant verlängern. Die Daten liefern eine Basis für eine prospektive klinische Studie.

Kernaussagen

  • OS unter Chemoimmuntherapie länger als unter den Vergleichsgruppen
  • RFS zwischen den Gruppen nicht signifikant verschieden
  • Häufigste UAW: hämatologische Toxizität; keine therapiebedingten Todesfälle

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 21.06.2025. Verfasst von Yuhuai Peng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory, Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University, Changsha, P. R. China. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Immunotherapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Project of Hunan Provincial Health Commission, Hunan Provincial People's Hospital RenShu fund.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives The prognosis of biliary tract cancers (BTC) after radical resection is still unsatisfactory. However, the clinical value of adjuvant therapy remains controversial. This retrospective study aimed to evaluate the clinical value of adjuvant chemotherapy and adjuvant chemoimmunotherapy in patients with BTC after radical resection.

Methods

Data from BTC patients who underwent radical resection were retrospectively obtained from Hunan Provincial People’s Hospital between January 2020 and July 2024. Patients were divided into observation group, adjuvant chemotherapy group, and adjuvant chemoimmunotherapy group according to the treatment received by the patient after surgery. Survival curves were determined by the Kaplan–Meier method. The COX proportional hazards regression model was used to determine independent prognostic risk factors. The adjuvant chemotherapy group and adjuvant chemoimmunotherapy group were analyzed by PSM at a 1:1 ratio.

Results

A total of 219 patients with BTC were reenrolled in this study, with 108 cases of iCCA, 39 cases of pCCA, 15 cases of DCCA, and 57 cases of GBC. Eighty-seven patients (39.73%) received surgery alone, 69 patients (31.51%) received postoperative adjuvant chemotherapy, and 63 patients (28.77%) received postoperative adjuvant chemoimmunotherapy. There was no different significance for median recurrence-free survival (RFS) in the 3 groups (13.20 vs 20.40 vs 19.68 months; P = .195). The median overall survival (OS) was the longest in the chemoimmunotherapy group (29.20 vs 31.5 vs 43.27 months; P = .003). After propensity score matching (PSM), there was no difference in median RFS in the 2 adjuvant groups (22.03 vs 19.87 months; P = .350). The median OS was longer in the chemoimmunotherapy group (45.27 vs 29.40 months; P = .015). In Cox analysis, lymph node metastasis, differentiation, and adjuvant treatment were the independent predictors of OS in patients with BTC. The most common adverse events were of any grade of hematologic toxicity. No drug-related deaths occurred in either group.

Conclusions

The safety of chemoimmunotherapy was acceptable and could significantly prolong the overall survival of BTC. These data provided a basis for an additional prospective clinical trial to evaluate the efficacy of chemoimmunotherapy in adjuvant therapy for BTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biliary Tract NeoplasmsImmunotherapyHumansFemaleMaleRetrospective StudiesChemotherapy, AdjuvantMiddle AgedAgedPrognosisAdult

Stichwörter der Autor:innen

adjuvant chemoimmunotherapyadjuvant chemotherapybiliary tract cancersoverall survivalrecurrence-free survival

Autor:innen und Institutionen

  • Central Laboratory, Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University, Changsha, P. R. China.
  • Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University, Changsha, P. R. China.
  • Department of Hepatobiliary Surgery, The Central Hospital of Shaoyang, Shaoyang, P. R. China.
  • The First school of Clinical Medicine, Lanzhou University, Lanzhou, P. R. China.
  • School of Medicine, University of Dundee, Ninewells Hospital, Dundee, UK.

ORCID-Profile: Yinghui Song

Förderung

  • National Natural Science Foundation of China
  • Project of Hunan Provincial Health Commission
  • Hunan Provincial People's Hospital RenShu fund
  • Hunan Provincial Natural Science Foundation of China
  • Hunan Provincial Key Laboratory of Prevention and Treatment of Biliary Tract Diseases
  • Hunan Province Innovation Guidance Project
  • Hunan Provincial People’s Hospital RenShu fund

Zitieren

APA

Peng, Y., Xia, G., Li, Y., Zhou, J., Liu, S., Peng, C., Tao, Y., Li, O., & Song, Y. (2025). Postoperative adjuvant chemotherapy and chemoimmunotherapy after radical resection for biliary tract cancer: a retrospective study. The Oncologist, 30(6). https://doi.org/10.1093/oncolo/oyaf163

Vancouver

Peng Y, Xia G, Li Y, Zhou J, Liu S, Peng C, et al. Postoperative adjuvant chemotherapy and chemoimmunotherapy after radical resection for biliary tract cancer: a retrospective study. The Oncologist. 2025;30(6). doi:10.1093/oncolo/oyaf163

BibTeX
@article{Peng2025,
  author = {Peng, Yuhuai and Xia, Guoyi and Li, Yufeng and Zhou, Jia and Liu, Sulai and Peng, Chuang and Tao, Yuewei and Li, Ou and Song, Yinghui},
  title = {Postoperative adjuvant chemotherapy and chemoimmunotherapy after radical resection for biliary tract cancer: a retrospective study},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {6},
  doi = {10.1093/oncolo/oyaf163}
}
Kostenlos starten →